Is Exemestano [INN-Spanish] Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use Exemestano [INN-Spanish]? Is Exemestano [INN-Spanish] safe for nursing mother and child? Does Exemestano [INN-Spanish] extracts into breast milk? Does Exemestano [INN-Spanish] has any long term or short term side effects on infants? Can Exemestano [INN-Spanish] influence milk supply or can Exemestano [INN-Spanish] decrease milk supply in lactating mothers?
Exemestano [INN-Spanish] lactation summary
![Exemestano [INN-Spanish] is dangerous in breastfeeding](/images/breastfeeding/dangerous-in-breastfeeding.jpg "Exemestano [INN-Spanish] breastfeeding")
- DrLact safety Score for Exemestano [INN-Spanish] is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of Exemestano [INN-Spanish] may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that Exemestano [INN-Spanish] may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using Exemestano [INN-Spanish] .
- Usage of Exemestano [INN-Spanish] is in contradiction to breastfeeding hence if it is must to use Exemestano [INN-Spanish] and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About Exemestano [INN-Spanish] usage in lactation
Steroidal aromatase inhibitor. Using this drug while breastfeeding in not recommended
Answer by DrLact: About Exemestano [INN-Spanish] usage in lactation
No information is available on the use of Exemestano [INN-Spanish] during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. The manufacturer recommends that breastfeeding be discontinued during Exemestano [INN-Spanish] therapy and for 1 month after the last dose.
Alternate Drugs
Bevacizumab(Low Risk)
Bleomycin(Dangerous)
Docetaxel(Dangerous)
Cisplatin(Unsafe)
Pazopanib(Unsafe)
Vinorelbine(Dangerous)
Busulfan(Dangerous)
Trastuzumab(Unsafe)
Dacarbazine(Dangerous)
Imatinib(Unsafe)
Thioguanine(Dangerous)
Erlotinib(Unsafe)
Cladribine(Dangerous)
Letrozole(Dangerous)
Azelaic Acid(Safe)
Dactinomycin(Dangerous)
Dasatinib(Unsafe)
Exemestane(Dangerous)
Vincristine(Dangerous)
Nilotinib(Unsafe)
Tamoxifen(Dangerous)
Ipilimumab(Unsafe)
Mitoxantrone(Dangerous)
Cetuximab(Unsafe)
Mercaptopurine(Safe)
Carboplatin(Dangerous)
Gemcitabine(Dangerous)
Paclitaxel(Dangerous)
Hydroxyurea(Low Risk)
Fluorouracil(Dangerous)
Etoposide(Dangerous)
Alemtuzumab(Low Risk)
Nivolumab(Unsafe)
Doxorubicin(Dangerous)
Rituximab(Low Risk)
Vinblastine(Dangerous)
Cyclophosphamide(Dangerous)
Letrozole(Dangerous)
Exemestane(Dangerous)